Denali Therapeutics Inc DNLI

$18.89 -0.84 (-4.26%)

Valuation

Market cap
3,162,541,000
Revenue TTM
$0
Net income TTM
$-512,540,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,309,600
Avg volume
1,779,150
Day's range
$18.80 – $19.60
Shares out
160,291,000
Stochastic %K
15%
Beta
1.08
Analysts
Strong Buy
Price target
$35.00

Price

Company profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (S...

Show more

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 866 8547
Website
https://www.denalitherapeutics.com
Address
161 Oyster Point Boulevard, South San Francisco, United States

Latest news

Stocktwits

notreload_ai Nov 13, 1:04 PM
Loop Capital upgraded $ADSK to Buy, PT $310 on improving demand. Wells Fargo starts $DNLI Overweight $35 PT for brain drug tech & approval. Baird upgraded $DPZ to Outperform, PT $400 on better sales and promos. https://notreload.xyz/wall-street-live-friday-november-13/
0 replies
Quantumup Nov 13, 11:53 AM
Wells Fargo🏁 $DNLI and said--We think we are approaching an inflection point w/ TfR technology given the approval of Avlayah, constructive FDA feedback on Zafi, & validating data from Roche's tronti in AD. Commercial assets provide a floor, see upside w/ AD. Initiate OW, PT $35. [PRTA IONS BCYC $RHBBY [TAK RGNX RARE SGMOQ [ESAIY - BIIB LLY ]]] DNLI has validated TfR technology with broad applicability. DNLI has pioneered transferrin receptor (TfR) technology with one FDA approved product, Avlayah (Hunter Syndrome). We now think DNLI is in a position to capitalize on their platform and accelerate drug development. We think expected cash flows from Avlayah, and soon zafi (Sanfilippo), provide a floor value to the stock, and expect advancement of assets in development in bigger markets (Alzheimer's disease) to re-rate shares higher.
0 replies
Merlintrader Nov 12, 8:26 PM
New on Merlintrader: the $DNLI stock hub. AVLAYAH sales were 17.8 million dollars in Q3, with 30-32 million guided for Q4, and Denali held about 1.0 billion of cash. Q3 profit included a one-time voucher-sale gain. UBS presentation on Nov 17. Full $DNLI stock hub: https://www.merlintrader.com/denali-therapeutics-dnli-stock-hub/ Not investment advice.
0 replies
topstockalerts Nov 9, 9:10 PM
Guggenheim analyst Yatin Suneja reiterated his Buy rating on Denali Therapeutics with a $200 price target, maintaining the biotech company as a top pick following its Q3 2026 results. The analyst views Denali as one of the most attractive small- and mid-cap immunology platforms, with significant long-term upside. The Phase III CAPTIVATE trial of claseprubart, a C1s inhibitor for chronic inflammatory demyelinating polyneuropathy (CIDP), remains on track. Part A is expected to require fewer than 200 patients to identify 128 responders for Part B, with approximately 185 patients estimated. Part A results are expected in late 2027, followed by Part B in late 2028. Meanwhile, the 46-patient Phase II MoMeNtum trial in multifocal motor neuropathy (MMN) is expected to deliver results in December 2026, potentially supporting Phase III development in 2027. Preliminary DNTH212 data are expected in Q1 2027, while DNTH312 remains on track for Phase I readiness by late 2027. $DNLI
1 replies
Rayvio_News_Filter Nov 9, 12:04 PM
$DNLI · $INM 🤝 Mentari Therapeutics closed its merger with InMed Pharmaceuticals and completed previously announced private placement financings with $490 million in gross proceeds, providing runway into 2029 and beyond. Timely market event
0 replies
GTA_Terminal Nov 8, 2:06 PM
Dark pool check on $DNLI: what traded off the exchanges in the latest session. The stock moved +1.8% on the day, so this wasn't happening in a quiet tape. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=DNLI&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=DNLI Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-denali-therapeutics-dnli?utm_source=stocktwits&utm_medium=social
0 replies
Rayvio_News_Filter Nov 6, 9:06 PM
$DNLI 🤝 InMed Pharmaceuticals Inc. completed its previously disclosed merger with privately held Mentari Therapeutics, Inc., with the combined company renamed Mentari Therapeutics, Inc. and shares expected to trade on Nasdaq under ticker MTRI on November 9, 2026. Curated for market relevance
0 replies
MisterRagnirLothbrok Nov 5, 12:59 AM
Ticker SCAG had huge news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $DNLI $VERU $DIS $ADGM Cx
0 replies